MedTrace Logo

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

NCT04372524 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2023-12-05

No results posted yet for this study

Summary

This study will validate a previously developed pediatric prognostic biomarker algorithm aimed at improving prediction of risk for the later development of chronic graft-versus-host disease (cGvHD) in children and young adults undergoing allogeneic hematopoietic stem cell transplant.

By developing an early risk stratification of patients into low-, intermediate-, and high-risk for future cGvHD development (based upon their biomarker profile, before the onset of cGvHD), pre-emptive therapies aimed at preventing the onset of cGvHD can be developed based upon an individual's biological risk profile.

This study will also continue research into diagnostic biomarkers of cGvHD, and begin work into biomarker models that predict clinical response to cGvHD therapies.

Conditions

  • Chronic Graft-versus-Host-Disease
  • Leukemia
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Blood Cancer
  • Non-Malignant Hematologic and Lymphocytic Disorder

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Kirk R Schultz, MD · University of British Columbia / BC Children's Hospital Research Institute

  • Andrew C Harris, MD · Memorial Sloan Kettering Cancer Center / Pediatric Stem Cell Transplantation and Cellular Therapies

Eligibility

Min Age
0 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2024-01-31
Completion
2025-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372524 on ClinicalTrials.gov